ArticleArchives of osteoporosis2023
The correlation between circulating growth differentiation factor 11 and the risk of osteopenia/osteoporosis in men.
Article in Archives of osteoporosis, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Our results suggest that the serum GDF11 concentration is significantly associated with the risk of bone metabolism dysfunction in men and may be a useful target for prediction of osteopenia/osteoporosis to enable prompt intervention for this common but invariably under- or misdiagnosed condition in men. PURPOSE: Male osteopenia/osteoporosis remains a neglected subject or is under- or misdiagnosed. Many studies have confirmed the role of growth differentiation factor 11 (GDF11) in bone metabolism, although its role in bone metabolism remains controversial. In this study, we aimed to investigate the association between serum GDF11 levels and the prevalence of osteopenia/osteoporosis (OP) in a male cohort and explore the possibility of GDF11 to be a useful target for prediction of osteopenia/osteoporosis to enable prompt intervention for this disease.
methodsThis cross-sectional study included 121 native Chinese men randomly aged 20-87 years, excluded the subjects who had the conditions of bone metabolism-related disease and administration of hormonal drugs, and grouped the subjects to OP and non-OP, based on the WHO definition and latest guidelines of OP. The serum GDF11 concentration was determined using a GDF11-specific immunoassay. Bone mineral density (BMD) was measured using dual-energy X-ray absorptiometry. Tartrate-resistant acid phosphatase 5b (TRAP-5b) were measured in serum samples with ELISA method.
resultsWe observed a negative correlation between serum GDF11 levels and age, a positive correlation between serum GDF11 levels and the femoral neck BMD, and a negative correlation between serum GDF11 levels and TRAP-5b in men. The prevalence and risk of OP were significantly higher in men with low serum GDF11 levels.
conclusionsThe serum GDF11 concentration is significantly associated with the risk of bone metabolism dysfunction and may be a useful target for prediction of OP in male cohort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.